Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche posted solid 2012 results and development of new cancer drugs continues apace, forecasting further sales and profit gains in 2013 and beyond – as long as government insurers can handle the abundance.
You may also be interested in...
Roche Follow-On Development Strategy Highlighted By Strong 1H Results
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.
Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s COO Daniel O’Day says. The firm’s moves into emerging markets are a lab for new methods, though the real test will come as the more expensive drugs are used in combination.
Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.